Been watching this healthcare drama unfold and it's actually pretty fascinating from a market perspective. Eli Lilly just put on a masterclass in earnings execution, then got immediately undercut by a competitor playing the price game hard.

Lilly's Q4 numbers were genuinely impressive. Revenue hit $19.3 billion, crushing the $17.9 billion consensus by a solid margin. Adjusted EPS came in at $7.54 versus $7.48 expected. But here's where it gets interesting - their 2026 guidance absolutely blew past what Wall Street was modeling. They're calling for $81.5 billion in revenue and $34.25 adjusted EPS, implying 25% and 41% growth respectively. Analysts had been penciling in just 19% revenue growth and 36% EPS growth. That's a meaningful beat on both fronts.

The injectable weight loss and diabetes market is where Lilly's really dominating right now. Their market share in the U.S. incretin space hit over 60% by end of 2025, up from nearly tied with Novo Nordisk just a year prior. Their tirzepatide product genuinely works better than the competition - we're talking almost 50% more weight loss compared to semaglutide. That's not a marginal difference, that's a real clinical advantage that doctors are noticing.

Now here's where the undercut comes in. Hims announced they're launching a generic version of Novo's oral semaglutide at $49 for month one, then $99 monthly. That's a hundred bucks cheaper than Novo's pricing and massively undercuts what Lilly plans to charge for their oral drug, which is supposed to hit somewhere between $149 and $399 depending on dosage. The market got spooked - Lilly shares dropped nearly 8% on the announcement.

But honestly, I think the panic might be overdone. UBS estimates there have been roughly 1 million prescriptions for compounded GLP-1s floating around, while Novo and Lilly combined have written about 100 million for their branded products. That's a massive gap. Hims could be annoying competition, sure, but the scale difference suggests they're not about to tank Lilly's growth trajectory, especially with orforglipron still pending approval for Q2 launch.

The consensus price target is sitting around $1,200, which implies about 18% upside. But analysts who updated their models right after earnings came in higher - averaging around $1,273, suggesting closer to 25% potential gain. With the oral drug launch coming soon and injectable momentum still strong, Lilly looks like it can weather this pricing pressure better than the market's initial reaction suggested.